Publications by authors named "Keith Dawson"

Claim this Profile
S
Sexual orientation and gender identity data: An observational study assessing the feasibility of SOGI collection in clinical research and patient assistance programs.
Isabel Brown, Thuan Tran, Audrey Funwie, Shilpen Patel, Keith Dawson

PLoS One· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R-index: a standardized representativeness metric for benchmarking diversity, equity, and inclusion in biopharmaceutical clinical trial development.
Spencer L James, Max Bourgognon, Patricia Pinto Vieira, Bruno Jolain, Sarah Bentouati, Keith Dawson

EClinicalMedicine· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma.
Stefan Knop, Monika Szarejko, Norbert Grząśko, Sara Bringhen, Karolin Trautmann-Grill, Keith M Dawson

EJHaem· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.
Matteo Bianchi, Christian Reichen, Amelie Croset, Stefanie Fischer, Aline Eggenschwiler, Keith M Dawson

Cancer Immunol Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deprescribing initiative of NSAIDs (DIN): Pharmacist-led interventions for pain management in a federal correctional setting.
Keith G Dawson, Vanessa Mok, Jason G M Wong, Alka Bhalla

Can Pharm J (Ott)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants.
Sylvia Rothenberger, Daniel L Hurdiss, Marcel Walser, Francesca Malvezzi, Jennifer Mayor, Keith M Dawson

Nat Biotechnol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
Stefanie Fischer, Thorsten O Götze, Aurelius Omlin, Richard D Baird, Keith M Dawson

JCO Precis Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
Aleksandar Sekulic, Simon Yoo, Ragini Kudchadkar, Julie Guillen, Gary Rogers, Keith Dawson

PLoS One· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.
Esther Drill, Annie Qiu, Sheila Shapouri, Tu My To, Arliene Ravelo, Keith Dawson

Oncology (Williston Park)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
Scott J Spencer, Gregory F Guzauskas, Federico FeLizzi, Aino Launonen, Keith Dawson

J Manag Care Spec Pharm· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobile Diabetes Telemedicine Clinics for Aboriginal First Nation People With Reported Diabetes in British Columbia.
Keith G Dawson, Andrew Jin, Matthew Summerskill, Dann Swann

Can J Diabetes· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
Richard D Baird, Constanza Linossi, Mark Middleton, Simon Lord, Adrian Harris, Keith M Dawson

J Clin Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance rituximab in Veterans with follicular lymphoma.
Ahmad S Halwani, Kelli M Rasmussen, Vikas Patil, Deborah Morreall, Catherine Li, Keith Dawson

Cancer Med· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Antibodies: The DARPin Drug Platform.
Michael T Stumpp, Keith M Dawson, H Kaspar Binz

BioDrugs· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.
Gregory F Guzauskas, Anthony Masaquel, Per-Olof Thuresson, Keith Dawson, David L Veenstra

Leuk Lymphoma· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study.
Brian K Link, Bann-Mo Day, Xiaolei Zhou, Andrew D Zelenetz, Keith L Dawson

Br J Haematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vismodegib Use in Clinical Practice: Analysis of a United States Medical Claims Database.
C William Hanke, Shivani K Mhatre, David Oliveri, Marko Zivkovic, Ivor Caro, Keith Dawson

J Drugs Dermatol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy.
Philip Hooper, Marie Carole Boucher, Alan Cruess, Keith G Dawson, Walter Delpero

Can J Ophthalmol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MP0250, a VEGF and HGF neutralizing DARPin molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models.
Ulrike Fiedler, Savira Ekawardhani, Andreas Cornelius, Pat Gilboy, Talitha R Bakker, Keith M Dawson

Oncotarget· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.
Ida Wong-Sefidan, Michelle Byrtek, Xiaolei Zhou, Jonathan W Friedberg, Christopher R Flowers, Keith L Dawson

Leuk Lymphoma· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States: Implications for Nursing Practice.
Keith Dawson

J Infus Nurs· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.
Chadi Nabhan, Xiaolei Zhou, Bann-Mo Day, Keith Dawson, Andrew D Zelenetz

Am J Hematol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agreement of Point-of-Care Capillary Glycated Hemoglobin Levels with Conventional Screening Tests for Diabetes Mellitus in a Canadian First Nations Population.
Jessica Mackenzie-Feder, Andrew Jin, David W Seccombe, Sandra Sirrs, Carolyne Neufeld, Keith G Dawson

Can J Diabetes· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab.
Keith Dawson, Mollie Moran, Kathleen Guindon, Hui Wan

Clin J Oncol Nurs· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
Loretta J Nastoupil, Rajni Sinha, Michelle Byrtek, Ryan Ziemiecki, Xiaolei Zhou, Keith Dawson

Br J Haematol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis